Investing the Efficacy of Amisulpride for Schizophrenia Treatment
- 1. Senior Resident, Department of Psychiatry ,DMCH, Darbhanga, Laheriasarai
- 2. Senior Resident, Department of Psychiatry, PMCH, Patna
- 3. Assistant Professor & Head, Department of Psychiatry, DMCH, Darbhanga, Laheriasarai
Description
Background: The study was performed at the Department of Pharmacology in collaboration with Department of Psychiatry, at DMCH Darbhanga. The maximum numbers of patients in were in reproductive age group that is in between 20 to 49 years. The mean age in Amisulpride group was 33.26(±10.23) years while in Olanzapine group it was 31.25 (±12.22) years. Schizophrenia was more common (80%) in younger (20-49years) age group. In our study the male /female ratio was 1.7. Our study supports the notion that Schizophrenia is more common in Married and Urban population. Only one patient from Olanzapine Group suffered Extrapyramidal symptoms of moderate severity requiring withdrawal from study.2 patients from Olanzapine group and 1 patient from Amisulpride group had Tremors and Akathesia of mild severity. There was no emergence of Extrapyramidal symptoms in rest of the patients (p>.05) Only one patient from Olanzapine Group suffered Extrapyramidal symptoms of moderate severity requiring withdrawal from study.2 patients from Olanzapine group and 1 patient from Amisulpride group had Tremors and Akathesia of mild severity. There was no emergence of Extrapyramidal symptoms in rest of the patients (p>.05)
Abstract (English)
Background: The study was performed at the Department of Pharmacology in collaboration with Department of Psychiatry, at DMCH Darbhanga. The maximum numbers of patients in were in reproductive age group that is in between 20 to 49 years. The mean age in Amisulpride group was 33.26(±10.23) years while in Olanzapine group it was 31.25 (±12.22) years. Schizophrenia was more common (80%) in younger (20-49years) age group. In our study the male /female ratio was 1.7. Our study supports the notion that Schizophrenia is more common in Married and Urban population. Only one patient from Olanzapine Group suffered Extrapyramidal symptoms of moderate severity requiring withdrawal from study.2 patients from Olanzapine group and 1 patient from Amisulpride group had Tremors and Akathesia of mild severity. There was no emergence of Extrapyramidal symptoms in rest of the patients (p>.05) Only one patient from Olanzapine Group suffered Extrapyramidal symptoms of moderate severity requiring withdrawal from study.2 patients from Olanzapine group and 1 patient from Amisulpride group had Tremors and Akathesia of mild severity. There was no emergence of Extrapyramidal symptoms in rest of the patients (p>.05)
Files
IJPCR,Vol16,Issue5,Article246.pdf
Files
(315.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3137ec56b0b06cfb07a913c77651b45b
|
315.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-28
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue5,Article246.pdf
- Development Status
- Active
References
- 1. Akhondzadeh, Shahin. 2006 Pharmacotherapy of Schizophrenia: The Past, Present and Future Current Drug Therapy, 1(1), pp. 1-7. 2. Babulas, V, Factor-Litvak, P, Goetz, R, Schaefer, CA, Brown, AS. 2006. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. American Journal of Psychiatry, 163(5),pp.927-9. 3. Danion, JM, Rein, W, Fleurot, O, and the Amisulpride Study Group, 1999 improvement ofSchizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride American Journal of Psychiatry, 156,pp.610- 616. 4. Lecrubier, Y, Boyer, P, Turjanski, S, Rein, W., 1997. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.Journal of Affect Disorder, 43(2),pp. 95-103. 5. Leucht, S, Pitschel-Walz, G, Engel, R, and Kissling, W., 2002. Amisulpride, an unusual atypical antipsychotic: a Meta-analysis of randomized controlled trials. American Journal of Psychiatry 159, pp. 180-190. 6. Loo, H, Poirier-Littre, MF, Theron, MF, Rein, W, and Fleurot, O., 1997.Amisulpride versus placebo in the medium-term treatment of the negative symptoms ofschizophrenia The British Journal of Psychiatry 170, pp.18-22. 7. Marder, SR, Meibach, RC. 1994. Risperidone in the treatment of schizophrenia. American Journal ofPsychiatry, 151 pp. 825–835. 8. Möller, HJ, Boyer, P. Fleurot, O. Rein, W. and PROD- ASLP Study Group., 1997 Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol, Psychopharmacology, 132(4), pp.396-401. 9. Paillere-Martinot, ML, Martinot, JL, and Aubin, F., 1995. Improvement of some schizophrenic deficit symptoms with low doses of Amisulpride American Journal of Psychiatry, 152, pp.130-134. 10. Timothy, JR. Lambert and David JC. 2003. Pharmacological approaches to the management of schizophrenia MJA, 178 (9), pp. S57- S61.